68 results
DEFM14A
HARP
Harpoon Therapeutics Inc
8 Feb 24
Proxy related to merger
7:00am
of the senior management and representatives of Harpoon regarding their assessment of the Internal Data, and conducted such financial studies and analyses … accounting for risk and probability adjustments reflecting Harpoon senior management’s assessment as to the probability of success of Harpoon’s pipeline
PREM14A
HARP
Harpoon Therapeutics Inc
29 Jan 24
Preliminary proxy related to merger
4:52pm
management and representatives of Harpoon regarding their assessment of the Internal Data, and conducted such financial studies and analyses and took … for risk and probability adjustments reflecting Harpoon senior management’s assessment as to the probability of success of Harpoon’s pipeline programs
8-K
EX-99.1
HARP
Harpoon Therapeutics Inc
26 Jan 24
Other Events
12:00am
prior to de-escalation of priming to 1 mg d Immune effector cell encephalopathy (ICE) score for ICANS assessment performed at Screening and 6 times … scan due to AE or PD ‡ Subject continuing treatment with only 1 disease assessment; not included in confirmed ORR ‡ ‡
Dr. Himisha Beltran -82.6
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
8:04am
, assessment or regulation of Taxes.
“Third Party” means any Person or “group” (as defined under Section 13(d) of the Exchange Act) of Persons, other … related to Security Incidents. The Company has timely remediated and addressed any and all audit or assessment findings identified as “critical” relating
8-K
EX-2.1
HARP
Harpoon Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
of which does not relate to Taxes.
“Taxing Authority” means any Governmental Authority responsible for the collection, administration, assessment … Incidents. The Company has timely remediated and addressed any and all audit or assessment findings identified as “critical” relating to cyber
8-K
EX-10.2
4w98chbk 0viqnp0po
23 Oct 23
Entry into a Material Definitive Agreement
7:45pm
8-K
EX-99.1
4gyy33rjbj1vqxj oya1
23 Oct 23
Other Events
8:00am
PRE 14A
y37spsj
14 Apr 23
Preliminary proxy
4:54pm
8-K
EX-99.2
nbzqn5y
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
cw38p7a57
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
82cqlir5
11 Jan 22
Other Events
6:16am